Technical Analysis for AGIO - Agios Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bearish Engulfing | Bearish | 0.02% | |
| NR7 | Range Contraction | 0.02% | |
| Inside Day | Range Contraction | 0.02% | |
| Wide Bands | Range Expansion | -0.86% | |
| Wide Bands | Range Expansion | 0.38% | |
| MACD Bullish Signal Line Cross | Bullish | -0.37% | |
| Wide Bands | Range Expansion | -0.37% | |
| Up 3 Days in a Row | Strength | -0.37% | |
| Up 4 Days in a Row | Strength | -0.37% | |
| Up 5 Days in a Row | Strength | -0.37% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 18 hours ago |
| Possible NR7 | about 20 hours ago |
| Down 2 % | about 23 hours ago |
| Fell Below Previous Day's Low | about 24 hours ago |
| Down 1% | about 24 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 10/31/2024
Agios Pharmaceuticals, Inc. Description
Agios Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics in the field of cancer metabolism and inborn errors of metabolism (IEMs) in the United States. Its products include AG-221, an oral inhibitor of the mutated isocitrate dehydrogenase (IDH) 2 protein for the treatment of patients with cancers that harbor IDH2 mutations, as well as for the Type II D-2 hydroxyglutaric aciduria treatment; AG-120, an oral inhibitor of the mutated IDH1 protein for the treatment of patients with cancers that harbor IDH1 mutations; and enzyme glutaminase that converts the nutrient glutamine into the metabolite glutamate. The company's products also comprise AG-348, an oral small molecule activator of PKR enzyme for the treatment of patients with pyruvate kinase deficiency. It has a collaboration agreement with Celgene Corporation. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Acid Hydrogen Metabolism Organic Chemistry Glutamate Inborn Errors Of Metabolism Pyruvate Kinase Deficiency
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 62.58 |
| 52 Week Low | 20.96 |
| Average Volume | 636,040 |
| 200-Day Moving Average | 41.26 |
| 50-Day Moving Average | 48.94 |
| 20-Day Moving Average | 56.26 |
| 10-Day Moving Average | 57.27 |
| Average True Range | 2.25 |
| RSI (14) | 66.56 |
| ADX | 30.9 |
| +DI | 31.35 |
| -DI | 16.14 |
| Chandelier Exit (Long, 3 ATRs) | 55.84 |
| Chandelier Exit (Short, 3 ATRs) | 49.99 |
| Upper Bollinger Bands | 62.85 |
| Lower Bollinger Band | 49.67 |
| Percent B (%b) | 0.7 |
| BandWidth | 23.43 |
| MACD Line | 2.87 |
| MACD Signal Line | 2.85 |
| MACD Histogram | 0.0208 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 61.56 | ||||
| Resistance 3 (R3) | 61.38 | 60.30 | 61.11 | ||
| Resistance 2 (R2) | 60.30 | 59.62 | 60.39 | 60.96 | |
| Resistance 1 (R1) | 59.59 | 59.20 | 59.95 | 59.77 | 60.81 |
| Pivot Point | 58.52 | 58.52 | 58.70 | 58.61 | 58.52 |
| Support 1 (S1) | 57.81 | 57.84 | 58.16 | 57.99 | 56.95 |
| Support 2 (S2) | 56.73 | 57.42 | 56.82 | 56.80 | |
| Support 3 (S3) | 56.02 | 56.73 | 56.65 | ||
| Support 4 (S4) | 56.20 |
